


Express Mail Label No.: ED 281274139 US

Date of Deposit: January 27, 2006

01-30-06 gfw  
Attorney Docket No. CST-201 CIP

PAIR Customer No.: 31012



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Rush *et al.*  
ASSIGNEE: Cell Signaling Technology, Inc.  
SERIAL NUMBER: 10/777,893 EXAMINER: P. Do  
FILING DATE: February 12, 2004 ART UNIT: 1641  
FOR: IMMUNOAFFINITY ISOLATION OF MODIFIED PEPTIDES FROM  
COMPLEX MIXTURES

January 27, 2006

Danvers, Massachusetts

Mail Stop AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Attached hereto for filing in the above-identified patent application are the following:

- ☒ Transmittal Letter (2 pages w/duplicate);
- ☒ Supplemental Information Disclosure Statement (3 pages);
- ☒ IDS Form – PTO 1449 (2 pages w/duplicate);
- ☒ References AB-AF; DB-DF ((10 references);
- ☒ Return Postcard.

Respectfully submitted,

Andrew J. Warner, Esq., Reg. No. 56,049  
Associate Intellectual Property Counsel  
CELL SIGNALING TECHNOLOGY, INC.

Dated: January 27, 2006

Express Mail Label No.: ED 282174139 US

Date of Deposit: January 27, 2006



Attorney Docket No.: CST-201 CIP

PAIR Customer No.: 31012

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Rush *et al*  
ASSIGNEE: CELL SIGNALING TECHNOLOGY, INC.  
SERIAL NUMBER: 10/777,893 EXAMINER: P. Do  
FILING DATE: February 12, 2004 ART UNIT: 1641  
FOR: IMMUNOAFFINITY ISOLATION OF MODIFIED PEPTIDES FROM  
COMPLEX MIXTURES

January 27, 2006  
Danvers, Massachusetts

Mail Stop AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references.

**U.S. Patent or Application Documents:**

6,379,970	Liebler, et al	04/30/2002
5,885,841	Higgs, Jr., et al	03/23/1999
6,451,591	Edwards, et al	09/17/2002
6,441,140	Comb, et al	08/7/2002
6,291,645	Shin, et al	09/18/2001

**Foreign Patent Documents:**

**Other Prior Art – Non Patent Literature Documents:**

Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
Kamps, MP, <i>et al.</i> , <i>Generation and Use of Anti-Phosphotyrosine Antibodies for Immunoblotting</i> , Methods in Enzymology, Vol. 201:101-110 (1991)
Stukenberg, <i>et al.</i> , <i>Systematic Identification of Mitotic Phosphoproteins</i> , Current Biology, Current Science Vol. 7, No. 5:338-348 (May 1997)
Ouyang, <i>et al.</i> , <i>Multi-site Phospho-typing of the Erb-2 Oncoprotein in Human Breast Cancer</i> , Molecular Diagnosis: A Journal Devoted to the Understanding of Human Disease Through the Clinical Application of Molecular Biology, Vol. 6, No. 1:17-25 (March 2001)
Yanagida, <i>et al.</i> , <i>Matrix Assisted Laser Desorption/Ionization-time of Flight-Mass Spectrometry Analysis of Proteins Detected by Anti-Phosphotyrosine Antibody on Two- Dimensional Gels of Fibroblast Cell Lysates After Tumor Necrosis Factor-alpha Stimulation</i> , Electrophoresis, Vol. 21, No. 9:1890-1898 (May 2000)
Godovac-Zimmerman Jasminka, <i>et al.</i> , <i>Functional Proteomics of Signal Transduction by Membrane Receptors</i> , Electrophoresis, Vol. 20, No. 4-5:952-961 (April 1999)

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☐ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97.

This Information Disclosure Statement is being filed:

- ☒ after the mailing of a first Office Action on the merits, but before the mailing date of a final Office Action, a Notice of Allowance, or an action that otherwise closes prosecution in the application; and
- ☐ is accompanied by the following statement:

☐ Applicant(s) hereby state(s) that each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement (37 C.F.R §1.97(e)(1)); or

☐ Applicant(s) hereby state(s) that no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned representative signing this certification after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in Rule 1.56(c) more than three months prior to the filing of this information disclosure (37 C.F.R. §1.97(e)(2)); and

☒ is accompanied by the fee set forth in 37 C.F.R. §1.17(p):

☐ a check for the required fee is enclosed herewith; or


☒ the Commissioner is hereby authorized to charge the required fee (and any other fees that may be due) to U.S. Deposit Account No. 50-1774, Ref. No. CST-201 CIP.

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-1774, Reference No. CST-201 CIP.

Respectfully submitted




Andrew J. Warner, Esq., Reg. No. 56,049  
Associate Intellectual Property Counsel  
CELL SIGNALING TECHNOLOGY, INC.

Dated: January 27, 2006

Modified Form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)



Application Number	10/777,893
Filing Date	February 12, 2004
First Named Inventor	Rush <i>et al.</i>
Group Art Unit	1641
Examiner Name	P. Do
Attorney Docket Number	CST-201 CIP

**U.S. PATENT DOCUMENTS**

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	AB	6,379,970	04/30/2002	Liebler, et al			04/30/1999
	AC	5,885,841	03/23/1999	Higgs, Jr., et al			09/11/1996
	AD	6,451,591	09/17/2002	Edwards, et al			03/12/2001
	AE	6,441,140	08/27/2002	Comb, et al			009/04/1998
	AF	6,291,645	09/18/2001	Shin, et al			07/19/1999

**U.S. CO-PENDING PATENT APPLICATIONS**

Exam Initials	Cite No.	U.S. Patent App. Serial No.	Status	Name of Applicant(s) and Assignee	Art Unit	Examiner	Filing Date

**FOREIGN PATENT DOCUMENTS**

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

**OTHER NON PATENT LITERATURE DOCUMENTS**

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	DB	Stukenberg, <i>et al.</i> , <i>Systematic Identification of Mitotic Phosphoproteins</i> , Current Biology, Current Science Vol. 7, No. 5:338-348 (May 1997)
	DC	Ouyang, <i>et al.</i> , <i>Multi-site Phospho-typing of the ErbB-2 Oncoprotein in Human Breast Cancer</i> , Molecular Diagnosis: A Journal Devoted to the Understanding of Human Disease Through the Clinical Application of Molecular Biology, Vol. 6, No. 1:17-25 (March 2001)
	DD	Yanagida, <i>et al.</i> , <i>Matrix Assisted Laser Desorption/Ionization-Time of Flight-Mass Spectrometry Analysis of Proteins Detected by Anti-Phosphotyrosine Antibody on Two-Dimensional Gels of Fibroblast Cell Lysates After Tumor Necrosis Factor-alpha Stimulation</i> , Electrophoresis, Vol. 21, No. 9:1890-1898 (May 2000)
	DE	Godovac-Zimmerman Jasminka, <i>et al.</i> , <i>Functional Proteomics of Signal Transduction by Membrane Receptors</i> , Electrophoresis, Vol. 20, No. 4-5:952-961 (April 1999)
	DF	Kamps, MP, <i>et al.</i> , <i>Generation and Use of Anti-Phosphotyrosine Antibodies for Immunoblotting</i> , Methods in Enzymology, Vol. 201:101-110 (1991)

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. 09/535,364 , filed March 24, 2000, U.S.S.N. 09/148,712, filed September 4, 1998 , and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.